Clinical study for Neo-Bilirubin started at Sachsska Children's Hospital
Calmark Sweden AB (publ) announces today that a new clinical study regarding Neo-Bilirubin has been started in cooperation with the research unit at children's hospital Sachsska barnsjukhuset, part of Södersjukhuset AB, Stockholm.The test Neo-Bilirubin was CE-marked on 21 April 2020 after satisfactory results were obtained in the research study carried out at Södersjukhuset. However, the study had to be closed prematurely due to reprioritisations of resources at Södersjukhuset as a result of the covid-19 pandemic, which meant that the study could not proceed as planned. As announced in